A B S T R A C T Washed human platelets were incubated with 0.1-1.0 U/ml human thrombin and the effects on adenyl cyclase activity and on a platelet membrane protein (designated thrombin-sensitive protein) were studied. Adenyl cyclase activity was decreased 70-90% when intact platelets were incubated with thrombin. The Ti for loss of adenyl cyclase activity was less than 15 sec at 1 U/ml thrombin. There was no decrease of adenyl cyclase activity when sonicated platelets or isolated membranes were incubated with these concentrations of thrombin. Loss of adenyl cyclase activity was relatively specific since the activities of other platelet membrane enzymes were unaffected by thrombin. Prior incubation of platelets with dibutyryl cyclic adenosine monophosphate (AMP), prostaglandin El, or theophylline protected adenyl cyclase from inhibition by thrombin.
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Incubation of intact but not disrupted platelets with thrombin resulted in the release of thrombin-sensitive protein from the platelet membrane. The rapid release of this protein (Ti < 15 sec) at low concentrations of thrombin suggested that removal of thrombin-sensitive protein from the platelet membrane is an integral part of the platelet release reaction. This hypothesis is supported by the parallel effects of thrombin on adenyl cyclase activity and thrombin-sensitive protein release in the presence of dibutyryl cyclic AMP, prostaglandin Ei, and theophylline at varying concentrations of thrombin.
INTRODUCTION
Previous studies from several laboratories have indicated that human platelets contain adenyl cyclase and cyclic nucleotide phosphodiesterase (cAMP phosphodiesterase)' (1) (2) (3) (4) (5) (6) . Compounds which affect the activity of these enzymes and, as a result, the concentrations of adenosine 3',5'-monophosphate (cyclic AMP, cAMP) in platelets also have marked effects on platelet aggregation (2, 6-10) and on the platelet release reaction (11) . For example, incubation of platelets with prostaglandin (PGE1), N6-2'-0-dibutyryl cyclic adenosine 3',5'-monophosphate (DBcAMP), or theophylline before addition of thrombin inhibits thrombin-induced platelet aggregation (9, 10, 12) and release (11) . These observations have led to the hypothesis that agents which inhibit platelet aggregation increase the concentration of cAMP in platelets by stimulating adenyl cyclase or by inhibiting cAMP phosphodiesterase, and agents which stimulate aggregation and release, decrease platelet cAMP by the opposite mechanisms. One difficulty in explaining the action of thrombin by this hypothesis is that 0.1-1.0 U/ml of thrombin induces aggregation and release in intact platelets while 10-200 U/ml of bovine thrombin are required to demonstrate inhibition of adenyl cyclase activity in disrupted platelet preparations (5, 9 ).
Recently we have described a thrombin-sensitive protein (TSP) which is located in the membrane fraction of human platelets and which rapidly disappears from the platelet membrane after addition of 0.1-1.0 U/ml thrombin to intact but not to disrupted platelets (13) .
75 150 300 j4 PLATELET MEMBRANE PROTEIN FIGURE 1 Intact platelets were incubated for 20 min with thrombin or without (control) thrombin, 1 U/ml. After sonication, the platelet membranes were isolated and assayed for adenyl cyclase activity with and without 75 mtug PGE1 in the reaction medium.
Since intact platelets are required to demonstrate this interaction, we postulated that intact platelets rather than preparations of platelet membranes might also be required to demonstrate an effect of low concentrations of thrombin on platelet adenyl cyclase activity.
In the current study we report that adenyl cyclase activity from human platelets is rapidly decreased by low concentrations of thrombin when thrombin is added to intact but not to disrupted platelets. Further, there is a striking parallel between the effect of thrombin on TSP and inhibition of adenyl cyclase. Both effects of thrombin are inhibited in parallel by prior incubation of platelets with PGEi, theophylline, and DBcAMP. In more recent experiments we have shown that TSP is actually released from the platelet membrane into the medium after incubation of intact platelets with thrombin.2 METHODS Preparation of platelets. Human platelets, collected and isolated as described previously (14) , were washed twice in an isotonic buffer, pH 6.5, containing 0.113 M NaCl, 0.0043 M K2HPO4, 0.0043 M Na2HPO4, 0.0244 M NaH2PO4, and 1 mg/ml glucose, and were resuspended in 0.154 M NaCl-0.154 M Tris Cl pH 7.4; 9: 1, with 1 mg/ml glucose. All experiments were carried out within 4 to 6 hr of initial blood collection. Suspensions of platelets (2-4 X 109/2 ml) were incubated in a shaking incubator at 37°C with various additions as noted below. After incubation, the cells were disrupted by sonication for 15 sec at 70% intensity with a Biosonik8 sonifier equipped with microprobe. The platelet membrane fraction was collected by centrifugation at 50,000 g for 20 min and the membrane pellets to be used for de- (18) . Membrane solubilization and electrophoresis were carried out as described previously using 220 ,ug protein from each membrane sample per 0.5 X 20 cm gel (13) . The gels were stained with Coomassie Brilliant Blue (19, 20) and destained electrophoretically (21) . Densitometry of the gels stained with Coomassie Brilliant Blue was carried out using a Gilford recording spectrophotometer5 at 555 mu with a Model 2410-S Gilford linear transport scanner. The recorder speed and sensitivity were adjusted so that an area of 1 cm2 corresponded to approximately 1 jsg protein (chart speed 2.5 cm/min, full scale 0-3.0 OD). The content of TSP in each gel was estimated by integrating the area under the densitometer peak. Initial experiments confirmed the observation that 1 U/ml of thrombin has no effect on adenyl cyclase activity in platelet membrane fractions. Adenyl cyclase activity was 1.09 and 1.04 mnumoles cAMP formed per milligram protein/10 min after incubation of platelet membranes with and without 1 U/ml thrombin for 20 min respectively. Thrombin at 100 U/ml did inhibit adenyl cyclase 50-75% as reported previously (5, 9) .
In contrast, when 1 U/ml of thrombin was added to intact platelets, marked inhibition of adenyl cyclase was detected (Fig. 1) . The degree of inhibition was similar with or without the addition of PGE1 or sodium fluoride. Adenyl cyclase activity was not inhibited when platelets were sonicated prior to the addition of thrombin. These results parallel our previous observations showing that p thrombin causes release of TSP from intact platelets but not from isolated platelet membranes (Fig. 2) . When cells were disrupted by several other techniques (13), similar results were obtained.
Time course of disappearance of TSP and inhibition of adenyl cyclase activity. The finding that thrombin did not affect disrupted platelets allowed for studies of the time course of the effects of thrombin on TSP release and inhibition of adenyl cyclase activity, since each of these reactions could be stopped by sonication of the incubation mixture. Results of these studies are shown in Fig. 3 . In this experiment adenyl cyclase was inhibited 42% by 15 sec and only 10% of initial activity remained after 2 min. TSP was released rapidly in this experiment with greater than 50% release by 15 sec and complete release by 2 min. We next attempted to quantitate TSP release using densitometry of SDS polyacrylamide gels.
Quantitative determination of protein content in polyacrylamide gels is usually not feasible with Coomassie Tables   I, II , and III. Prior incubation of platelets with 1 ug/ml PGE1 caused almost 50% inhibition of release of TSP by 1 U/ml thrombin and completely prevented release by 0.2 U/ml thrombin (Table I) . At this concentration PGE, did not prevent inhibition of adenyl cyclase activity by 1 U/ml thrombin, but decreased the inhibition of adenyl cyclase activity by 0.2 U/ml thrombin from 71 to 20%. A concentration of 0.1 ig/ml PGE1 caused 23% inhibition of release of TSP by 1 U/ml thrombin and prevented release of TSP by 0.2 U/ml thrombin. At 0.1 Ag/ml, PGE1 did not prevent inhibition of adenyl cyclase activity by 1 U/ml thrombin, but caused a decrease in inhibition of adenyl cyclase activity by 0.2 U/ml thrombin from 71 to 49%. Thus, PGE, inhibited thrombin-induced release of TSP more effectively than it inhibited the effect of thrombin on platelet adenyl cyclase activity.
Prior incubation of platelets with 5.5 mm theophylline decreased the release of TSP by 1 U/ml thrombin from 86 to 50% and caused a parallel decrease in inhibition of adenyl cyclase activity (Table II) Platelet suspensions were incubated with PGE1 for 20 min before adding thrombin for an additional 9 min. Platelets were then sonicated and the membranes isolated and assayed for adenyl cyclase activity as described in Methods. Adenyl cyclase was assayed with 75 m,ug PGE1 in the reaction medium. SDS polyacrylamide electrophoresis and densitometry of gels for quantitation of TSP were carried out as described in Methods.
theophylline presumably acts by inhibiting cAMP phosphodiesterase, we measured activity of this enzyme in sonicates of platelets which had been incubated with and without thrombin. Thrombin had no effect on the activity of cAMP phosphodiesterase. When platelets were incubated with 1 mm DBcAMP for 20 min before the addition of 1 U/ml thrombin, the release of TSP was decreased from 68 to 57% while inhibition of platelet adenyl cyclase activity was decreased from 77 to 47% (Table III) . At 0.2 U/ml thrombin, 1 mM DBcAMP decreased the release of TSP from 57 to 7% while inhibition of adenyl cyclase activity was decreased from 67 to 22%. When platelets were preincubated with 1 mm 5'-AMP or adenosine there was no inhibition of thrombin-induced TSP release or adenyl cyclase inhibition.
The possibility that PGE1, DBcAMP, and theophylline might have a direct inhibitory effect on thrombin was excluded by experiments showing that these compounds did not affect thrombin activity in catalyzing the clotting of fibrinogen.
Effects of thrombin on platelet enzymes. In order to assess the specificity of the effect of thrombin on adenyl cyclase, the activities of several enzymes from platelet membranes were examined after incubating intact platelets with thrombin. There was no significant effect of thrombin on the activity of (Na+ + K+ + Mg2+) -ATPase, Ca2+-ATPase, 5' nucleotidase, Mg2-ATPase, or bis p-nitrophenol phosphatase (Table IV) . There was also no effect of thrombin on the activity of the two soluble enzymes, glucose 6-phosphate dehydrogenase and lactic dehydrogenase. In contrast adenyl cyclase was inhibited 77% by thrombin indicating that the effect of thrombin on platelet membranes is relatively specific for adenyl cyclase. DISCUSSION Numerous previous experiments suggest that thrombininduced platelet aggregation and release may be mediated by a fall in the concentration of platelet cAMP. However, Zieve and Greenough (5), and Saltzman and Levine (9) , have shown that high concentrations of bovine thrombin (10-200 U/ml) are required to inhibit adenyl cyclase in isolated platelet membranes. We have confirmed these observations using human thrombin and have now shown that low concentrations of human thrombin (< 1 U/ml) will inhibit adenyl cyclase when it is incubated with intact platelets. This inhibition of adenyl cyclase occurs rapidly with a T-& of less than 15 sec, and is relatively specific since the activities of several other enzymes from platelet membranes are unaffected by thrombin (Table IV) . Furthermore, preincubation of platelets with DBcAMP, PGE1, or theophylline protects adenyl cyclase from inhibition by thrombin. This protection is competitive with thrombin since increasing concentrations of thrombin result in adenyl cyclase inhibition even in the presence of these compounds. Wolfe and Shulman (11) have shown that PGE1, DBcAMP, and theophylline competitively inhibit the thrombin-induced platelet release reaction. Release of Ca++ and nucleotides occurs rapidly and precedes visible platelet aggregation. Competitive inhibition of the effect of thrombin on the platelet release reaction parallels the competitive inhibition of the effect of thrombin on inhibition of adenyl cyclase.
In a previous study of the effects of thrombin on human platelets we demonstrated that incubation of intact but not disrupted platelets with thrombin resulted in the disappearance of a major protein (TSP) from the platelet membrane (13) . The rapid release of TSP from platelet membranes at low concentrations of thrombin suggests that removal of TSP from the platelet membrane is an integral part of the platelet release reaction. This hypothesis is further supported by the parallel effects of thrombin on TSP release and adenyl cyclase inactivation. Thus TSP is released and adenyl cyclase is inhibited when thrombin is incubated with intact platelets, but neither effect is noted when disrupted platelets or isolated membranes are used. When TSP release and inhibition of adenyl cyclase activity are compared using different incubation times and concentrations of thrombin, there is a striking correlation between these two parameters (Figs. 5 and 6 ). Further correlation between TSP release and adenyl cyclase inhibition is noted in experiments using DBcAMP, PGE1, and theophylline, although there was a tendency for the inhibition of TSP release to be greater than the protection of adenyl cyclase activity suggesting partial dissociation between these phenomena.
Neither the nature of the relationship between TSP and adenyl cyclase nor of the interaction of thrombin with the platelet has been defined. Thrombin may act initially on TSP, adenyl cyclase, or on some other component of the platelet membrane. The initial effect of thrombin might be to alter the conformation of the platelet membrane which in turn results in release of TSP, inactivation of adenyl cyclase, the platelet release reaction, and platelet aggregation. The fact that TSP release and adenyl cyclase inhibition by thrombin require an intact membrane suggests that these reactions may be complex and involve the interactions between multiple components of a structurally and functionally intact membrane system. There are several mechanisms by which TSP and adenyl cyclase may be related. Thrombin might act primarily to release TSP resulting in structural changes in the platelet membrane which in turn lead to inactivation of adenyl cyclase by any of several mechanisms including inhibition by throm-bin or some other membrane component. The possibility that TSP is a part of adenyl cyclase has not been excluded although released TSP does not have any adenyl cyclase activity (i.e. there is no adenyl cyclase activity in incubation supernatants after thrombin treatment of intact platelets). Alternatively, the primary effect of thrombin might be to inactivate adenyl cyclase in the platelet membrane. The subsequent change in concentrations of cAMP in the membrane might secondarily lead to release of TSP. The parallel protection of adenyl cyclase activity and TSP release by agents which maintain cAMP levels (DBcAMP, PGE1, and theophylline) would support this mechanism. This hypothesis can also be tested further by using other agents known to cause a fall in platelet cAMP levels such as epinephrine or collagen. Finally it is possible that TSP release accompanies platelet aggregation from any cause. Thus, while platelet aggregation may follow adenyl cyclase inactivation under physiological conditions, other nonphysiologic aggregating agents may also release TSP, since we have recently shown that erythrophytohemagglutinin from kidney beans causes platelet aggregation and releases TSP. In these experiments there was marked platelet aggregation but inconsistent release of TSP and decrease in adenyl cyclase activity ranging from 0-50%.
Recently we have isolated TSP both from platelet membranes and from platelet incubation medium after TSP release by thrombin! The protein has been partially characterized and its relation to platelet function in coagulation is under study.
